Trials / Terminated
TerminatedNCT00547274
Dyslipidemia in Type 2 Diabetes (0767-034)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0767 |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2003-11-01
- Completion
- 2003-11-01
- First posted
- 2007-10-22
- Last updated
- 2015-06-12
Source: ClinicalTrials.gov record NCT00547274. Inclusion in this directory is not an endorsement.